Xiang Hong, Zuo Jiaxin, Guo Fangyue, Dong Deshi
Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University, Dalian, China.
College of Pharmacy, Dalian Medical University, Dalian, China.
Chin Med. 2020 Aug 26;15:88. doi: 10.1186/s13020-020-00370-6. eCollection 2020.
Rhubarb (also named Rhei or Dahuang), one of the most ancient and important herbs in traditional Chinese medicine (TCM), belongs to the genus from the Polygonaceae family, and its application can be traced back to 270 BC in "". Rhubarb has long been used as an antibacterial, anti-inflammatory, anti-fibrotic and anticancer medicine in China. However, for a variety of reasons, such as origin, variety and processing methods, there are differences in the effective components of rhubarb, which eventually lead to decreased quality and poor efficacy. Additionally, although some papers have reviewed the relationship between the active ingredients of rhubarb and pharmacologic actions, most studies have concentrated on one or several aspects, although there has been great progress in rhubarb research in recent years. Therefore, this review aims to summarize recent studies on the geographic distribution, taxonomic identification, pharmacology, clinical applications and safety issues related to rhubarb and provide insights into the further development and application of rhubarb in the future.
大黄(又称 Rhei 或 Dahuang)是传统中医中最古老、最重要的草药之一,属于蓼科植物属,其应用可追溯到公元前 270 年的《》。在中国,大黄长期以来一直被用作抗菌、抗炎、抗纤维化和抗癌药物。然而,由于产地、品种和加工方法等多种原因,大黄的有效成分存在差异,最终导致质量下降和疗效不佳。此外,虽然一些论文综述了大黄活性成分与药理作用之间的关系,但大多数研究都集中在一个或几个方面,尽管近年来大黄研究取得了很大进展。因此,本综述旨在总结近年来关于大黄的地理分布、分类鉴定、药理学、临床应用和安全性问题的研究,并为大黄未来的进一步开发和应用提供见解。